Abstract
Mutations in p110α (gene, PIK3CA) occur in ∼40% of HR+/HER2– BC. GDC-0077 is a potent p110α-isoform selective inhibitor that degrades mutant (mut) p110α and elicits anti-tumour activity in PIK3CAmut preclinical models alone and with endocrine therapy (ET). We present a preliminary co-analysis of PI3K pathway biomarkers and clinical outcomes from patients (pts) with PIK3CAmut HR+/HER2– BC in an ongoing open-label, phase I/Ib dose-escalation study of GDC-0077, with ET (letrozole/fulvestrant) +/– palbociclib (NCT03006172; data cut 1 Jan 2020).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
